Skip to content

Multi-center clinical study on the intervention of traditional Chinese medicine on Hashimoto's Thyroiditis with the Same Treatment of Liver and Spleen

Multi-center clinical study on the intervention of traditional Chinese medicine on Hashimoto's Thyroiditis with the Same Treatment of Liver and Spleen

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070184
Enrollment
Unknown
Registered
2023-04-04
Start date
2023-04-08
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hashimoto's thyroiditis

Interventions

treatment group:Kangjia Recipe
Control group:Kangjia Recipe Placebo

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) They met the diagnostic criteria of Hashimoto thyroiditis based on the guidelines for the diagnosis and treatment of thyroid diseases in China 2) The TCM dialectical belongs to the syndrome of liver stagnation and spleen deficiency; 3) Age = 18 and = 65 years; Gender not restricted 4) T3, T4, FT3, FT4 in the normal range of the tested values, TSH < 10 m IU / L; 5) And aspartate transaminase (AST) and alanine transaminase (ALT) = 3 × ULN Creatinine = 1.5uln;

Exclusion criteria

Exclusion criteria: 1) patients with poorly controlled systolic blood pressure (SBP) >160 MMHG or diastolic blood pressure (DBP) >100 MMHG; 2) patients who have had or are suffering from hyperthyroidism or hypothyroidism; Or postoperative hormone replacement therapy for thyroid tumors; 3) patients with myocardial infarction, heart failure or unstable angina pectoris within 6 months before enrollment; 4) patients with a history of stroke within 6 months before enrollment; 5) pregnant or lactating women; 6) Chronic alcohol abuse, drug dependence, and mental illness patients; 7) patients with a history of cancer; 8) patients with a known allergy to the trial drug or its components; 9) have participated or are participating in other interventional clinical research within one month before enrollment; 10) The investigator considered it inappropriate to participate in the study.

Design outcomes

Primary

MeasureTime frame
TPOAb;

Secondary

MeasureTime frame
TGAb;TSH;T3;T4;FT3;FT4;Thyroid B ultrasound;IL-17;TCM syndrome score;Quality of Life scale score;FOXP3;

Countries

China

Contacts

Public ContactYanming He

Department of Endocrinology,Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM

heyanming176@163.com15921747271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026